print-logo
Logo
  • Healthcare Consultants
  • Healthcare Managers
  • Who we are Arrow Down
    • About us
    • Our team
    • News & events
  • What we do Arrow Down
    • Overview
    • Market Access
    • Medical Affairs
    • Government Affairs
    • Commercial Excellence
    • Patient Affairs
  • Insights Arrow Down
    • Publications
    • Project cases
    • Early Asset Strategy
    • Value Pull-through
    • Environment Transformation
  • Careers Arrow Down
    • Why join us
    • FAQ
  • Contact
  • Search Icon
  • Healthcare Consultants
  • Healthcare Managers
  • Search Icon
  • Search
Back to Our team

Darrin Benjumea

Director | New York, US

Bild von Darrin Benjumea

Contact

  • mail_icon d.benjumea@executiveinsight.ch
  • linkedin_icon LinkedIn-Profile

Focus Area

Darrin focuses in the design and implementation of Integrated Evidence Planning frameworks and strategy. He is an experienced healthcare strategist and consultant, specializing in real-world evidence (RWE) and HEOR tactics and strategies, with heavy prior experience in developing evidence for the access and reimbursement of therapies for solid-tumor oncology and rare diseases.

He has led and supported the development and execution of integrated evidence generation plans and subsequent evidence activities to demonstrate product value across product lifecycle stages and patient, physician, payer, and policy audiences. 

Education

MPH (Epidemiology) - Columbia University, New York, USA

BS (Biochemistry) - University of North Carolina at Chapel Hill, North Carolina, USA

Languages

English, French, Spanish, Kabyle

An extroverted introvert with a real que sera sera mentality

Select Peer-reviewed publications


Rare Disease:

Loftus J, Wogen J, Benjumea D, Jhingran P, Chen Y, Alvir J, Majnrajch MP, Takasawa K.
Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in Japan.
PLoS One. 2025;20(8):e0324728. Published 2025 Aug 14. doi:10.1371/journal.pone.0324728 

Loftus J, Wogen J, Oliveri D, Benjumea D, Jhingran P, Chen Y, Alvir J Rivero-Sanz E, Kowalik JC, Wajnrajch MP.
Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in the UK.
Front Endocrinol (Lausanne). 2022;13:1014743. Published 2022 Nov 3. doi:10.3389/fendo.2022.1014743

Miller BS, Loftus J, Kelkar M, Shrestha S, Parzynski C, Benjumea D, Wogen J, Jhingran P, Alvir J, Gupta A, Wajnrajch M.
Impact of Daily Growth Hormone Adherence on Height Velocity Among Children With Growth Hormone Deficiency (GHD)
Endocr Pract. 2024 Sep;30(9):837-846. doi: 10.1016/j.eprac.2024.05.012. Epub 2024 May 29. PMID: 38821179.

Masri A, Chen Y, Colavecchia AC, Benjumea D, Crowley A, Jhingran P, Kent M, Wogen J, Pankratova C, Alvir J, Bhambri R.
Coexisting Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Real-World Evaluation of Clinical Characteristics and Outcomes.
J Am Heart Assoc. 2025;14(2):e033251. doi:10.1161/JAHA.123.033251

Kato T, Ines M, Minamisawa M, Benjumea D, Keohane D, Alvir J, Kim R, Chen Y, Peixoto T, Kent M, Wogen J, Ishii T, Crowley A, Sugino T, Izumiya Y.
Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan.
ESC Heart Fail. 2024 Oct;11(5):2881-2888. doi: 10.1002/ehf2.14736. Epub 2024 May 23. PMID: 38783561; PMCID: PMC11424365.

Bhambri R, Colavecchia AC, Bruno M, Chen Y, Alvir J, Roy A, Kemner J, Crowley A, Benjumea D, Gilstrap L.
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States.
Am J Cardiovasc Drugs. 2023;23(2):197-206. doi:10.1007/s40256-022-00563-4

Roy A, Peterson A, Marchant N, Alvir J, Bhambri R, Bredl Z, Benjumea D, Kemner J, Parasuraman B.
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort.
J Manag Care Spec Pharm. 2022;28(7):766-777. doi:10.18553/jmcp.2022.28.7.766

Roy A, Peterson A, Marchant N, Alvir J, Bhambri R, Lynn J, Benjumea D, Prasad S, O’Brien A, Chen Y, Kemner J, Parasuraman B.
Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database.
Patient Prefer Adherence. 2022;16:1115-1129. Published 2022 Apr 29. doi:10.2147/PPA.S352332

Oncology:

Moon HH, Aragon-Ching JB, Thompson A, Abraham A, Vlahiotis A, Ike C, Benjumea D, Shao A, Sun H, Kearney M, Gharibian N, Hanson S, Li B, Kirker M, Grivas P.
Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy.
Urol Oncol. Published online July 16, 2025. doi:10.1016/j.urolonc.2025.05.014

Moon HH, Kirker M, Abraham A, Vlahiotis A, Bhanegaonkar A, Ike C, Benjumea D, Kim C, Sun H, Kearney M, Chandrasekar S, Li B, Thakkar S.
Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinoma.
Oncologist. 2025;30(7):oyaf071. doi:10.1093/oncolo/oyaf071

Dennis MJ, Abrahami D, Vieira MC, Benjumea D, Boyd M, Shao A, Kelton J, Patel SP.
Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non-Small Cell Lung Cancer in the United States.
JCO Precis Oncol. 2025;9:e2400449. doi:10.1200/PO-24-00449

Infectious Disease:

Scott A, Puzniak L, Murphy MV, Benjumea D, Rava A, Benigno M, Allen KE, Stanford RH, Manuel F, Chambers R, Reimbaeva M, Ansari W, Cha-Silva AS, Draica F.
Assessment of clinical characteristics and mortality in patients hospitalized with SARS-CoV-2 from January 2022 to November 2022, when Omicron variants were predominant in the United States.
Curr Med Res Opin. 2025;41(1):71-82. doi:10.1080/03007995.2024.2442515

Cai B, Tillotson G, Benjumea D, Callahan P, Echols R.
The Burden of Bloodstream Infections due to Stenotrophomonas maltophilia in the United States: A Large, Retrospective Database Study.
Open Forum Infectious Diseases. 2020; 1-7. https://doi.org/10.1093/ofid/ofaa141
 

Translating Patient Priorities into JCA Success: Lessons from Early Reports
Publication

Translating Patient Priorities into JCA Success: Lessons from Early Reports

Share this page
  • linkedin_icon
  • mail_icon
  • print_icon

We use cookies to ensure we give you the best experience on our website. Detailed information on the use of cookies, and how you can disable them, is provided in our Privacy Policy. By using this site or clicking on "OK", you consent to the use of cookies.

OK
arrow_up

How can we help?

Contact us

Our offices

Careers

Footer Logo
  • Who we are
  • What we do
  • Insights
  • Careers
  • Contact
  • Terms of use
  • Privacy policy
  • Imprint

2026 Executive Insight. All rights reserved.